CAR-T cell therapy uses a patient’s own cells to fight blood cancers. How a simple idea was terribly complex to realize.
Three innovative spins on CAR-T cell therapy promise more benefits and reduced damage from cellular cancer treatments.
For all their potential, CAR-T cell cancer therapies face significant obstacles. Bijan Nejadnik of Eureka Therapeutics explains one powerful method to overcome them.
Cheng Liu, CEO and Chairman of Eureka Therapeutics, discusses how to beat both cancer and viral infections with treatments inspired by nature.
The next iterations of T cell therapy will go after intracellular targets that until now have been unavailable.